长链非编码RNANR_026829调控S100A9介导肺腺癌脊柱转移的作用及机制研究
批准号:
81772855
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
董健
依托单位:
学科分类:
肿瘤表观遗传
结题年份:
2021
批准年份:
2017
项目状态:
已结题
项目参与者:
林红、周健、江立波、姜允琦、王厚磊、梁运、边冲、陈谦
中文摘要
恶性肿瘤容易发生脊柱转移(Spinal Metastasis,SM),肺癌尤为多见,亚型肺腺癌占50%,机理不明。lncRNA在多层面调控基因表达,是否参与SM未见报道。前期芯片结果示lncRNANR_026829在转移瘤表达明显高于原发瘤。NR_026829与S100A9基因位点相邻,NR_026829沉默能抑制S100A9表达,显示S100A9可能为潜在作用靶点,免疫组化显示S100A9在转移瘤高表达。预实验提示NR_026829可能调控S100A9介导肺腺癌脊柱转移。本课题以免疫抑制细胞(MDSC)和循环肿瘤细胞(CTC)为研究对象,采用组蛋白修饰转录调控等分子生物学和免疫学手段,研究NR_026829通过调控S100A9直接趋化CTC脊柱转移、和间接募集MDSC形成免疫抑制微环境双重途径在SM中的机理;用脊柱转移瘤动物模型进一步分析NR_026829作用,为早期干预SM提供新靶点。
英文摘要
Malignant tumor is prone to spinal metastases (SM), especially occurred in adenocarcinoma, which accounts for about 50%. But the mechanism for this phenomenon is not clear. LncRNA regulates gene expression at multiple levels, however, there is not report about whether it involves in SM or not remains unclear. In our preliminary work, high-throughput microarray analysis showed that lncRNANR_026829 was more expressed in SM than that in primary tumors. NR_026829 was closed to gene of S100A9 and NR_026829 silencing could inhibite the expression of S100A9. So S100A9 maybe the target of NR_026829. Immunohistochemistry showed that S100A9 was highly expressed in metastatic neoplasm. The results of preliminary work suggest that NR_026829 may regulate S100A9 to mediate spinal metastasis in lung adenocarcinoma. Therefore immunosuppressive cell (MDSC) and circulating tumor cell (CTC) are selected for this study to explore the mechanism for NR_026829 regulating S100A9 to effect on CTC and MDSC about formation of immunosuppressive microenvironment by molecular biology and immunology methods, such as transcriptional regulation of histone modified. Further analysis about NR_026829 is taken to provide new target for early intervention on SM with animal model.
恶性肿瘤容易发生脊柱转移(Spinal Metastasis,SM),肺癌尤为多见,肺癌亚型中肺腺癌占50%,机理不明。lncRNA在多层面调控基因表达,是否参与SM未见报道。课题前期对临床原发及脊柱转移肺腺癌肿瘤标本芯片结果显示lncRNANR_026829在转移瘤表达明显高于原发瘤。进一步进行免疫组化、WB、PCR实验验证上述结果,显示lncRNANR_026829、S100A9在转移瘤高表达。生存分析表明lncRNANR_026829高表达患者生存期短。lncRNANR_026829与S100A9基因位点相邻,lncRNANR_026829沉默能抑制S100A9表达,提示S100A9可能为潜在作用靶点,通过RNA-pulldown及建立过表达、敲低细胞证实,lncRNANR_026829可促进S100A9表达。进一步实验证实,lncRNANR_026829、S100A9可抑制肺腺癌凋亡、促进肺腺癌增殖。预实验提示lncRNANR_026829可能调控S100A9介导肺腺癌脊柱转移,利用上述细胞系构建肺腺癌脊柱转移小鼠模型证实,lncRNANR_026829可促进S100A9表达可促进肺腺癌细胞脊柱转移。本课题以免疫抑制细胞(MDSC)和循环肿瘤细胞(CTC)为研究对象,采用组蛋白修饰转录调控等分子生物学和免疫学手段,研究lncRNANR_026829通过调控S100A9直接趋化CTC脊柱转移、和间接募集MDSC形成免疫抑制微环境双重途径在SM中的机理;用脊柱转移瘤动物模型进一步分析lncRNANR_026829作用,为早期干预SM提供新靶点。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
登录
查看更多内容
The emergence of new prognostic scores in lung cancer patients with spinal metastasis: A 12-year single-center retrospective study.
肺癌脊柱转移患者新预后评分的出现:12年单中心回顾性研究
DOI:
10.7150/jca.60821
发表时间:
2021
期刊:
Journal of Cancer
影响因子:
3.9
作者:
[Chen Q, Chen X, Zhou L, Chen F, Hu A, Wang K, Liang H, Jiang L, Li X, Dong J]
通讯作者:
Dong J
Are older patients with solitary spinal metastases fit for total en-bloc surgery?
患有孤立性脊柱转移瘤的老年患者是否适合进行整块手术?
DOI:
10.1016/j.clineuro.2018.04.007
发表时间:
2018-07-01
期刊:
CLINICAL NEUROLOGY AND NEUROSURGERY
影响因子:
1.9
作者:
[Liu, Peng, Jiang, Libo, Dong, Jian]
通讯作者:
Dong, Jian
Surgical Outcomes and Prognostic Factors for Metastatic Spine Hepatocellular Carcinoma
脊柱转移性肝细胞癌的手术结果和预后因素
DOI:
10.1016/j.wneu.2018.10.226
发表时间:
2019
期刊:
WORLD NEUROSURGERY
影响因子:
2
作者:
[Wang Sheng-Xing, Wang Hou-Lei, Lin Kai-Yuan, Bian Chong, Sun Chi, Dong Jian]
通讯作者:
Dong Jian
CX3CL1 Induces Vertebral Microvascular Barrier Dysfunction via the Src/P115-RhoGEF/ROCK Signaling Pathway
CX3CL1 通过 Src/P115-RhoGEF/ROCK 信号通路诱导椎体微血管屏障功能障碍
DOI:
10.3389/fncel.2020.00096
发表时间:
2020-04
期刊:
Frontiers in Cellular Neuroscience
影响因子:
5.3
作者:
[Lei Yi, Yun Liang, Quanming Zhao, Houlei Wang, Jian Dong]
通讯作者:
Jian Dong
CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
CX3CL1/fractalkine通过激活Src/FAK通路增强前列腺癌脊柱转移
DOI:
10.3892/ijo.2018.4487
发表时间:
2018-10
期刊:
International journal of oncology
影响因子:
5.2
作者:
[Liu P, Liang Y, Jiang L, Wang H, Wang S, Dong J]
通讯作者:
Dong J
共 8 条
整合素ITGB3促进PD-L1表达在非小细胞肺癌脊柱转移瘤治疗中的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:董健
-
依托单位:
ICAM-1介导CX3CL1促进CTC-血小板簇跨椎体微血管内皮细胞外渗的机制研究
-
批准号:81972508
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:董健
-
依托单位:
椎体红骨髓分泌的CX3CL1调控Src/FAK通路对脊柱转移性肿瘤的促进作用及分子机制
-
批准号:81572629
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2015
-
负责人:董健
-
依托单位:
质子感知受体OGR1介导胞内Ca2+水平调控椎间盘终板软骨细胞退变及其作用机制
-
批准号:81372002
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2013
-
负责人:董健
-
依托单位:
多肽修饰温敏型水凝胶复合携TGF- - β1的脂肪间充质干细胞修复兔椎间盘软骨终板退变
-
批准号:31170925
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:董健
-
依托单位:
纳米复合材料制备的生物活性全降解分层自锁定颈椎融合器的研制及其成骨性能研究
-
批准号:30970718
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2009
-
负责人:董健
-
依托单位:
生物相容性人工骨的组织工程学构筑和移植实验研究
-
批准号:30271262
-
项目类别:面上项目
-
资助金额:19.0万元
-
批准年份:2002
-
负责人:董健
-
依托单位:
国内基金
海外基金